Rapid and Low-Cost Detection and Quantification of SARS-CoV-2 Antibody Titers of ICU Patients with Respiratory Deterioration Using a Handheld Thermo-Photonic Device.

While research suggests that COVID-19 vaccines are effective in producing anti-SARS-CoV-2 antibodies that reduce the risk of COVID-19 and its potentially severe complications, how long these antibodies persist after the infection/vaccination is unknown. Longitudinal studies and rapid and scalable platforms are needed for large-scale sero-diagnosis and vaccine evaluation. In this study, we examine the efficacy of our recently-developed handheld thermo-photonic device for rapid and low-cost assessment of the adaptive immune response of COVID+ and COVID- patients admitted to the intensive care unit (ICU) at a local hospital due to respiratory deterioration. Antibody testing included detection and quantification of IgG and IgM via thermo-photonic sensing of a commercially available COVID-19 IgG/IgM rapid test as well as standard measurements with quantitative enzyme-linked immunosorbent assays (qELISA). The results demonstrate that the thermo-photonic reader in conjunction with COVID-19 IgG/IgM test cassettes can detect and quantify IgG levels in COVID-19 antibody assays within the clinically relevant range and with a high correlation to those obtained from qELISA. We also found that the IgG antibody is more reliable for detecting individuals with an adaptive immune response to SARS-CoV-2 compared to the IgM antibody. The developed reader offers a low-cost, portable, and scalable solution for accessing the antibody titer of individuals against SARS-CoV-2 and can be used in local hospital settings.

Handheld Thermo-Photonic Device for Rapid, Low-Cost, and On-Site Detection and Quantification of Anti-SARS-CoV-2 Antibody.

With the emergence of vaccines and antibody therapeutics, rapid and scalable platforms are needed to quantify the antibody response of individuals. Lateral flow immunoassay (LFA) based test strips provide a rapid, low-cost, and point-of-care approach to antibody testing against the SARS-CoV-2 virus. These convenient and scalable tests, however, are qualitative in nature and cannot quantify the immune response of the infected and/or vaccinated individuals. This study reports on the development of a rapid, low cost and portable thermo-photonic device that enables sensitive detection and quantification of antibody levels using commercially available COVID-19 Antibody LFAs. Unlike conventional LFA readers, the developed technology is based on sensing the infrared thermal radiation of tag gold nanoparticles following laser excitation (aka photothermal response). Our proof-of-concept results with humanized monoclonal anti-SARS-CoV-2 Spike receptor-binding domain (RBD) IgG demonstrate that the thermo-photonic technology can detect and quantify antibody concentrations within the clinically relevant range and with a limit of detection of [Formula: see text]/ml. The reader in conjunction with antibody LFAs offers a low-cost, portable, and scalable solution for assessment of the degree of immunity in populations, quality control of convalescent plasma donations for antibody therapeutics, and monitoring the immune response of infected individuals and vaccine recipients.

Low-Cost Active Thermography using Cellphone Infrared Cameras: from Early Detection of Dental Caries to Quantification of THC in Oral Fluid.

Active thermography (AT) is a widely studied non-destructive testing method for the characterization and evaluation of biological and industrial materials. Despite its broad range of potential applications, commercialization and wide-spread adaption of AT has long been impeded by the cost and size of infrared (IR) cameras. In this paper, we demonstrate that this cost and size limitation can be overcome using cell-phone attachment IR cameras. A software development kit (SDK) is developed that controls camera attributes through a simple USB interface and acquires camera frames at a constant frame rate up to 33 fps. To demonstrate the performance of our low-cost AT system, we report and discuss our experimental results on two high impact potential applications. The first set of experiments is conducted on a dental sample to investigate the clinical potential of the developed low-cost technology for detecting early dental caries, while the second set of experiments is conducted on the oral-fluid based lateral flow immunoassay to determine the viability of our technology for detecting and quantifying cannabis consumption at the point-of-care. Our results suggest achievement of reliable performance in the low-cost platform, comparable to those of costly and bulky research-grade systems, paving the way for translation of AT techniques to market.

Thermographic detection and quantification of THC in oral fluid at unprecedented low concentrations.

With recent changes in the legalization of cannabis around the world, there is an urgent need for rapid, yet sensitive, screening devices for testing drivers and employees under the influence of cannabis at the roadside and at the workplace, respectively. Oral fluid lateral flow immunoassays (LFAs) have recently been explored for such applications. While LFAs offer on-site, low-cost and rapid detection of tetrahydrocannabinol (THC), their nominal detection threshold is about 25 ng/ml, which is well above the 1-5 ng/ml per se limits set by regulations. In this paper, we report on the development of a thermo-photonic imaging system that utilizes the commercially available low-cost LFAs but offers detection of THC at unprecedented low concentrations. Our reader technology examines photothermal responses of gold nanoparticles (GNPs) in LFA through lock-in thermography (LIT). Our results (n = 300) suggest that the demodulation of localized surface plasmon resonance responses of GNPs captured by infrared cameras allows for detection of THC concentrations as low as 2 ng/ml with 96% accuracy. Quantification of THC concentration is also achievable with our technology through calibration.